SANOFI-AVENTIS (EPA:SAN) FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of =50%
Transparency directive : regulatory news
22/02/2021 19:00
Tweeter
FDA approves Libtayo® (cemiplimab-rwlc)...
22/02/2021 19:00
FDA approves Libtayo® (Cemiplimab-rwlc) as...
09/02/2021 23:15
Availability of the Q4 2020 Memorandum for...
17/12/2020 22:30
Sanofi: Information concerning the total...
30/11/2020 22:37
Sanofi: Disclosure of trading in own shares
30/11/2020 22:15
Sanofi: Disclosure of trading in own shares
23/11/2020 22:08
Sanofi and GSK in advanced discussions with...
31/07/2020 21:20
Sanofi and GSK selected for Operation Warp...
31/07/2020 13:00
Availability of the Pre-quarterly Results...
06/07/2020 22:30
Sanofi and Regeneron provide update on...
02/07/2020 22:30
Read all communications published by the company